Efficacy of pegylated interferon alpha-2a combined with tenofovir in treatment of hepatitis B virus/hepatitis C virus co-infection
Li Shuang
Li Ying
Xie Fei
Abstract：Objective To investigate the efficacy and mechanism of pegylated interferon α-2a (PEG-IFNα-2a) combined with tenofovir in the treatment of hepatitis B virus (HBV)/Hepatitis C virus (HCV) co-infection. Methods A total of 122 patients with HBV/HCV co-infection treated in Shaanxi Provincial People's Hospital from July to December 2022 were selected as the research subjects and divided into the monotherapy group (PEG-IFN-α-2a only) and combined group (PEG-IFN-α-2a combined with tenofo-vir) by using the random number table method,with 61 in each group. Virological response rate,liver function index,liver fibrosis index,oxidative stress index and immune index were compared between the two groups. Results The HBV complete virological response rate and HCV completion virological response rate were significantly higher in the combined group than in the monotherapy group (78.69％ vs 57.38％,93.44％ vs 77.05％) (P<0.05). After treatment,the levels of alanine aminotransferase (ALT),aspartate aminotransferase (AST) and total bilirubin (TBIL) were (33.27±8.95) U·L-1,(31.47±11.45) U·L-1,(14.47±3.55) μmol·L-1,in the com-bined group. They were all lower than those of (45.91±12.64) U·L-1,(40.57±12.58) U·L-1,(19.84±3.25) μmol·L-1 in the monotherapy group and the differences were statistically significant (P<0.05). As for liver fibrosis indexes,the levels of hyaluronic acid (HA),type Ⅳ collagen (Ⅳ-C),type Ⅲ procollagen (PCⅢ) and laminin (LN) were (115.24±25.92) μg·L-1,(51.85±15.27) ng·mL-1,(97.85±12.55) μg·L-1 and (68.82±18.38) ng·mL-1 in the combined group. They were all lower than those of (194.25±21.48) μg·L-1,(69.27±14.69) ng·mL-1,(114.72±16.92) μg·L-1 and (81.46±17.46) ng·mL-1 in the monotherapy group and the differences were statistically significant (P<0.05). For the oxidative stress indexes,the levels of MAD and NO were (5.38±2.38) nmol·L-1 and (52.72±13.27) ng·L-1 in the combination group and they were lower than those of (9.44±3.04) nmol·L-1 and (71.47±15.82) ng·L-1 in the monotherapy group,showing statistically significant difference (P<0.05). The levels of immune indices of regulatory T cells (Treg) and Treg/helper T cells 17 (Th17) were (5.23±0.34)％ and (4.03±0.25) in the combined group,which were significantly lower than those of (5.78±0.29)％ and (4.47±0.32) in the monotherapy group (P<0.05). Conclusion PEG-IFNα-2a combined with tenofovir is effective in the treat-ment of HBV/HCV co-infection because it can improve the efficacy of virus clearance,protect liver function and alleviate liver fibro-sis. The mechanism of which might be related to the inhibition of oxidative stress and immune regulation.
Keywords：PEG-IFN α-2aTenofovirHepatitisLiver functionOxidative stressImmunity
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 738-742 )